Ingredion's £2.7B Tate & Lyle acquisition to redefine specialty ingredient market

London, United Kingdom — 08 June 2026

The board of Tate & Lyle has unanimously endorsed Ingredion's cash offer, valuing the UK specialty ingredients enterprise at approximately £2.7 billion. This acquisition, implying an enterprise value of £3.7 billion, aims to establish a global leader across critical functional areas including texture, sugar reduction, mouthfeel, sweetening, and fortification. The combined group would generate approximately US$9.9 billion in revenue and US$1.8 billion in adjusted EBITDA, positioning it to better serve food and beverage manufacturers in their reformulation efforts for healthier, affordable products. This consolidation is a direct response to prevailing consumer demands and industry pressures on product innovation.

Ingredion anticipates this deal will expand its specialty ingredients platform, leveraging Tate & Lyle's multi-ingredient systems, recipe development, and sweetening expertise. According to Jim Zallie, Ingredion's Chairman, President, and CEO, the merger will enhance innovation capabilities and geographic reach across the Americas, Europe, the Middle East, Africa, and Asia Pacific. This integrated supply network promises faster, more reliable, and cost-efficient ingredient solutions for customers. Tate & Lyle's strategic shift from commodity ingredients to specialty solutions, marked by its 2022-2024 divestment of its Americas Primary Products business and 2024 acquisition of CP Kelco, underpins this alignment.

Integration is projected to yield annual run-rate net cost synergies of approximately US$130 million, fully achievable by the end of 2030, against one-time costs of US$175 million. These savings are expected across SG&A and cost of goods sold, encompassing procurement, logistics, IT, and management expenses. Ingredion forecasts the transaction to be accretive to adjusted earnings per share in the first year post-completion, exceeding 15% in the first full fiscal year. Financing will utilise existing cash, new debt, and a committed bridge facility, aiming for a pro forma net leverage of around three times net debt-to-adjusted EBITDA, reducing this to 2.5x within 18 months.

Against a backdrop of challenging market conditions, characterised by weakened consumer sentiment and reduced near-term expectations for many ingredient and CPG companies, the acquisition offers a definitive cash value to Tate & Lyle shareholders. The company reported a 3% revenue and pro forma adjusted EBITDA decline for the year ended 31 March 2026, despite achieving over US$50 million in productivity savings. This trend highlights the increasing pressure on market players to consolidate for scale and efficiency.

What this means for United Kingdom

UK supplement and food manufacturers will face a consolidated specialty ingredient market post-acquisition, potentially altering procurement dynamics. Brand owners should anticipate revised MOQs and potentially longer lead times for specific ingredient categories as the combined entity optimises its supply chain. The increased scale of Ingredion may lead to more competitive pricing for high-volume ingredients, impacting smaller, niche UK ingredient suppliers. Regulatory teams should monitor the antitrust approval process, which is expected to conclude in late 2027, for any stipulations that could influence ingredient sourcing. This presents a challenge for independent formulators; however, it also offers opportunities for streamlined ingredient sourcing from a single, comprehensive supplier.

What to watch next

Monitor Ingredion's progress towards securing antitrust approvals, with transaction completion targeted for the second half of 2027.

Observe the integration of Tate & Lyle's ingredient portfolio into Ingredion's existing offerings, particularly how the US$130 million in cost synergies manifests in market pricing by 2030.

For more on UK formulation and manufacturing best practice, learn more at Supplement Factory.